MCID: HRT032
MIFTS: 75

Heart Disease

Categories: Cardiovascular diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 15 17
Congenital Heart Disease 12 29 54 6 15 17 71
Heart Failure 54 6 42 62 17 71 32
Congenital Heart Defects 12 29 6 42 3 62
Heart Diseases 54 42 43 15 71
Congenital Heart Defect 12 6
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 39
Congenital Heart Disorder 74
Heart Defects, Congenital 43
Heart Disease, Congenital 39
Congestive Heart Failure 71
Heart Defects Congenital 54
Heart-Congenital Defect 12
Heart Malformation 12
Heart Defects 15
Heart Defect 12

Classifications:



External Ids:

Disease Ontology 12 DOID:114 DOID:1682
ICD9CM 34 429.9 746.9
NCIt 49 C3079 C34666
SNOMED-CT 67 56265001
UMLS 71 C0018798 C0018799 C0018801 more

Summaries for Heart Disease

MedlinePlus : 42 If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks. Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease. You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk: Control your blood pressure Lower your cholesterol Don't smoke Get enough exercise NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart disease, is related to heart valve disease and lipoprotein quantitative trait locus, and has symptoms including edema, tremor and chest pain. An important gene associated with Heart Disease is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are MicroRNAs in cancer and Cardiac Progenitor Differentiation. The drugs Pancrelipase and Tenecteplase have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney.

CDC : 3 Congenital heart defects (CHDs) are conditions that are present at birth and can affect the structure of a baby's heart and the way it works. They are the most common type of birth defect. As medical care and treatment have advanced, infants with congenital heart defects are living longer and healthier lives. Many now are living into adulthood.

PubMed Health : 62 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 74 A congenital heart defect (CHD), also known as a congenital heart anomaly and congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5 Congenital Heart Defects, Multiple Types, 7

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2729)
# Related Disease Score Top Affiliating Genes
1 heart valve disease 34.4 NKX2-5 MYH6 MIR21 MIR195
2 lipoprotein quantitative trait locus 34.0 NKX2-5 MYH6 MIR21 GATA4
3 aortic valve disease 1 33.5 NKX2-5 MYH6 MIR21 MIR195 H19 GATA4
4 patent ductus arteriosus 1 33.4 NKX2-5 MYH6 GATA4
5 dilated cardiomyopathy 33.4 NKX2-5 MYH6 MIR214 MIR196A2 MHRT GATA4
6 double outlet right ventricle 33.3 NKX2-5 MYH6 GATA4
7 hypoplastic left heart syndrome 33.3 NKX2-5 MYH6 GATA4
8 holt-oram syndrome 33.1 NKX2-5 MYH6 GATA4
9 heart septal defect 32.9 NKX2-5 MYH6 GATA4
10 total anomalous pulmonary venous return 1 32.8 NKX2-5 GATA4
11 atrial standstill 1 32.7 MYH6 MIR320A GATA4
12 aortic valve disease 2 32.7 NKX2-5 MYH6 MIR21 MIR195 GATA4
13 eisenmenger syndrome 32.6 NKX2-5 GATA4
14 tricuspid atresia 32.6 NKX2-5 GATA4
15 atrioventricular block 32.6 NKX2-5 MHRT GATA4
16 atrial heart septal defect 32.5 NKX2-5 MYH6 GATA4
17 left ventricular noncompaction 32.1 NKX2-5 MYH6 MHRT GATA4
18 ebstein anomaly 32.0 NKX2-5 MYH6 GATA4
19 patent foramen ovale 31.8 NKX2-5 MYH6 GATA4
20 arteries, anomalies of 31.6 MIR23A MIR214 MIR210 MIR21
21 peripartum cardiomyopathy 31.1 MIR210 MIR21 MIR195
22 noonan syndrome with multiple lentigines 31.0 NKX2-5 MYH6 GATA4
23 heart, malformation of 30.9 NKX2-5 MYH6
24 intrinsic cardiomyopathy 30.9 NKX2-5 MYH6 MIR21 GATA4
25 polymyositis 30.8 MIR214 MIR210 MIR21
26 dermatomyositis 30.8 MIR214 MIR210 MIR21
27 aortic aneurysm, familial abdominal, 1 30.7 MIR23A MIR195 H19
28 leukemia, chronic lymphocytic 30.5 MIR214 MIR21 MIR196A2 MIR195 ABL1
29 leukemia, acute myeloid 30.3 MIR320A MIR23A MIR210 MIR21 MIR195 HOTAIR
30 inclusion body myositis 30.3 MIR214 MIR21 BACE1-AS
31 rectum cancer 30.2 MIR23A MIR214 MIR21
32 adrenocortical carcinoma, hereditary 30.2 MIR214 MIR195 H19
33 nervous system disease 30.1 MIR23A MIR214 MIR210 MIR21
34 diffuse large b-cell lymphoma 30.1 MIR320A MIR214 MIR210 MIR21 HOTAIR
35 kidney cancer 30.1 MIR214 MIR210 MIR21 HOTAIR H19
36 gastrointestinal system disease 30.1 MIR23A MIR214 MIR210 MIR21 MIR195
37 central nervous system disease 30.0 MIR23A MIR210 MIR21 H19
38 bladder disease 30.0 MIR23A MIR214 MIR21 MIR195
39 atrial septal defect 4 29.9 NKX2-5 H19
40 gastrointestinal system cancer 29.7 MIR23A MIR214 MIR210 MIR21 MIR195 HOTAIR
41 renal cell carcinoma, nonpapillary 29.7 MIR23A MIR214 MIR210 MIR21 MIR195 HOTAIR
42 coronary heart disease 1 12.8
43 congenital heart defects, multiple types, 4 12.7
44 deafness, congenital heart defects, and posterior embryotoxon 12.7
45 congenital heart defects, multiple types, 3 12.7
46 short stature, developmental delay, and congenital heart defects 12.7
47 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 12.7
48 congenital heart defects and ectodermal dysplasia 12.7
49 multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects 12.7
50 hypertensive heart disease 12.7

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 308)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


edema, tremor, chest pain, angina pectoris, syncope, equilibration disorder

Drugs & Therapeutics for Heart Disease

PubMed Health treatment related to Heart Disease: 62

Although many children who have congenital heart defects don't need treatment , some do. Doctors repair congenital heart defects with catheter procedures or surgery . Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects. The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health. Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1075)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4 53608-75-6
2
Tenecteplase Approved Phase 4 191588-94-0
3
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
4 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
5
Zopiclone Approved Phase 4 43200-80-2 5735
6
Tirofiban Approved Phase 4 144494-65-5 60947
7
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
8
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
9
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
10
tannic acid Approved Phase 4 1401-55-4
11
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
12
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
15
Glyburide Approved Phase 4 10238-21-8 3488
16
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
17
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
18
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
21
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
22
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
23
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
24
Alogliptin Approved Phase 4 850649-61-5 11450633
25
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
26
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
27
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
28
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
29
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
30
Fenofibrate Approved Phase 4 49562-28-9 3339
31
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
32
Ticagrelor Approved Phase 4 274693-27-5 9871419
33
Doxazosin Approved Phase 4 74191-85-8 3157
34
Trandolapril Approved Phase 4 87679-37-6 5484727
35
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
36
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
37
Manidipine Approved, Investigational Phase 4 89226-50-6
38
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
39
Magnesium citrate Approved Phase 4 3344-18-1
40 Apricot Approved Phase 4
41
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
42
Chloral hydrate Approved, Illicit, Investigational, Vet_approved Phase 4 302-17-0 2707
43
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
44
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
45
Cosyntropin Approved Phase 4 16960-16-0 16129617
46
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
47
Probucol Approved, Investigational Phase 4 23288-49-5 4912
48
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
49
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
50 Ancrod Approved, Investigational Phase 4 9046-56-4

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases Unknown status NCT02527811 Phase 4 Ulinastatin
2 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
3 The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial. Unknown status NCT02299063 Phase 4 Dexmedetomidine;0.9% NaCl
4 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
5 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
6 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
7 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
8 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
9 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
10 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Unknown status NCT02797340 Phase 4 Metformin
11 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
12 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
13 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
14 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
15 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
16 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
17 A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study of the Pre-Operative Effect of Sildenafil Citrate on Pulmonary Related Complications Following Cardiopulmonary Bypass in Children Undergoing Cardiac Surgical Repair. Unknown status NCT00350441 Phase 4 Sildenafil Citrate
18 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
19 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
20 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
21 Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery Unknown status NCT00388245 Phase 4
22 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
23 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
24 Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications Unknown status NCT01682291 Phase 4
25 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
26 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
27 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
28 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
29 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
30 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
31 A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus Unknown status NCT03159559 Phase 4 Lipo-PGE1
32 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
33 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
34 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
35 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
36 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
37 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
38 Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) Unknown status NCT03486561 Phase 4 Ranolazine
39 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
40 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
41 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
42 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
43 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
44 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
45 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
46 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
47 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
48 Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Unknown status NCT03574857 Phase 4 Metolazone Oral Tablet;Chlorothiazide Injection
49 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
50 Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy Unknown status NCT03380520 Phase 4 Ferric Carboxymaltose;Placebo

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trichlormethiazide
valsartan

Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 29
2 Congenital Heart Defects 29

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

40
Heart, Testes, Kidney, Endothelial, Lung, Brain, Bone

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 62095)
# Title Authors PMID Year
1
Advances in the Management of Acute Decompensated Heart Failure. 61 42
32505255 2020
2
Cardiac imaging in congenital heart disease during the coronavirus disease-2019 pandemic: recommendations from the Working Group on Congenital Heart Disease of the Italian Society of Cardiology. 61 42
32487868 2020
3
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. 46 61
20837903 2010
4
Cardiovascular Consequences of Acute Kidney Injury. 42
32492305 2020
5
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). 42
32359771 2020
6
2019-Novel Coronavirus-Related Acute Cardiac Injury Cannot Be Ignored. 42
32415481 2020
7
A multi-center, randomized, double-blind, placebo-parallel controlled trial for the efficacy and safety of shenfuqiangxin pills in the treatment of chronic heart failure (Heart-Kidney yang deficiency syndrome). 42
32481305 2020
8
Cardiovigilance in COVID 19. 42
32515382 2020
9
Using Zebrafish to Analyze the Genetic and Environmental Etiologies of Congenital Heart Defects. 42
32304074 2020
10
MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. 46
20837890 2010
11
Effects of myosin heavy chain manipulation in experimental heart failure. 61 54
19854200 2010
12
Myostatin: an overlooked player in heart failure? 54 61
20348549 2010
13
Heart failure and pulmonary hypertension. 54 61
20347789 2010
14
[Novel GATA4 mutations identified in patients with congenital heart disease]. 54 61
20450724 2010
15
Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. 54 61
20211335 2010
16
Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? 61 54
20156936 2010
17
Novel treatment strategy with direct renin inhibition against heart failure. 61 54
20228725 2010
18
Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. 61 54
20233990 2010
19
NKX2.5 mutations in patients with non-syndromic congenital heart disease. 54 61
19073351 2010
20
[Polymorphism of eNOS and iNOS Genes and Chronic Heart Failure in Patients With Ischemic Heart Disease]. 61 54
20459417 2010
21
Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. 54 61
19945058 2010
22
Endogenous erythropoietin and outcome in heart failure. 61 54
20048213 2010
23
Phosphodiesterase inhibition in heart failure. 54 61
19096931 2009
24
Beta-adrenergic blockers for chronic heart failure. 54 61
19829179 2009
25
Newer biomarkers in heart failure. 61 54
19631181 2009
26
Growth-differentiation factor-15 in heart failure. 61 54
19631178 2009
27
ST2 and adrenomedullin in heart failure. 61 54
19631176 2009
28
Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. 54 61
19255799 2009
29
Plasma urocortin 1 in human heart failure. 61 54
19808377 2009
30
Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. 46
19514064 2009
31
Cystatin C in acute heart failure without advanced renal impairment. 61 54
19393984 2009
32
Can adiponectin be a novel metabolic biomarker for heart failure? 61 54
19465781 2009
33
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 61 54
19377497 2009
34
MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. 46
19380620 2009
35
Recent insights on chronic heart failure, cachexia and nutrition. 61 54
19363338 2009
36
Plasma atrial natriuretic peptide in healthy calves and calves with congenital heart disease. 61 54
19658257 2009
37
The role of IL-1 in the pathogenesis of heart disease. 61 54
19479203 2009
38
[The mechanism of TBX5 abnormal expression in simple congenital heart disease]. 61 54
19586889 2009
39
Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease. 61 54
19258379 2009
40
Is erythropoietin behind maladaptive anemic heart failure? 61 54
19168730 2009
41
GATA4 and NKX2.5 gene analysis in Chinese Uygur patients with congenital heart disease. 54 61
19302747 2009
42
Energy metabolism in heart failure and remodelling. 61 54
18987051 2009
43
Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). 54 61
19165564 2009
44
[Erythropoietin in patients with chronic heart failure]. 54 61
19469252 2009
45
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. 46
19043405 2008
46
Uric acid, xanthine oxidase and heart failure: unresolved issues. 61 54
19010082 2008
47
Anemia in heart failure: to treat or not to treat? 61 54
19026176 2008
48
[Heart hypertrophy and heart failure--experimental findings for arrhythmogenesis]. 54 61
19085808 2008
49
GATA4 mutations in 486 Chinese patients with congenital heart disease. 54 61
18672102 2008
50
Erythropoietin, haemoglobin, heart failure, and mortality. 54 61
18786914 2008

Variations for Heart Disease

ClinVar genetic disease variations for Heart Disease:

6 (show top 50) (show all 61) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GATA4 NM_002052.5(GATA4):c.910-55T>CSNV Pathogenic 433018 rs1554498312 8:11612500-11612500 8:11754991-11754991
2 GATA4 NM_002052.5(GATA4):c.997+103G>TSNV Pathogenic 433019 rs113049875 8:11612745-11612745 8:11755236-11755236
3 GATA4 NM_002052.5(GATA4):c.998-26G>ASNV Pathogenic 433021 rs1554498708 8:11614418-11614418 8:11756909-11756909
4 GATA4 NM_002052.5(GATA4):c.*1168T>CSNV Pathogenic 433025 rs549543886 8:11617152-11617152 8:11759643-11759643
5 MYH6 NM_002471.3(MYH6):c.1410+1G>ASNV Pathogenic 561059 rs1566513862 14:23869917-23869917 14:23400708-23400708
6 NKX2-5 NM_004387.4(NKX2-5):c.182C>G (p.Ala61Gly)SNV Pathogenic 219170 rs864321650 5:172661905-172661905 5:173234902-173234902
7 GATA4 NM_002052.5(GATA4):c.23C>A (p.Ala8Asp)SNV Pathogenic 219226 rs864321698 8:11565844-11565844 8:11708335-11708335
8 GATA4 NM_002052.5(GATA4):c.25G>A (p.Ala9Thr)SNV Pathogenic 219227 rs864321699 8:11565846-11565846 8:11708337-11708337
9 GATA4 NM_002052.5(GATA4):c.27C>A (p.Ala9=)SNV Pathogenic 219231 rs864321703 8:11565848-11565848 8:11708339-11708339
10 GATA4 NM_002052.5(GATA4):c.383A>T (p.Glu128Val)SNV Pathogenic 219228 rs864321700 8:11566204-11566204 8:11708695-11708695
11 GATA4 NM_002052.5(GATA4):c.397A>T (p.Ser133Cys)SNV Pathogenic 219229 rs864321701 8:11566218-11566218 8:11708709-11708709
12 GATA4 NM_002052.5(GATA4):c.682T>A (p.Trp228Arg)SNV Pathogenic 219230 rs864321702 8:11606493-11606493 8:11748984-11748984
13 GATA4 NM_002052.5(GATA4):c.997+2T>GSNV Pathogenic 219233 rs864321705 8:11612644-11612644 8:11755135-11755135
14 GATA4 NM_002052.5(GATA4):c.1263C>T (p.Ser421=)SNV Pathogenic 219232 rs864321704 8:11615918-11615918 8:11758409-11758409
15 NKX2-5 NM_004387.4(NKX2-5):c.443C>A (p.Ala148Glu)SNV Pathogenic 219169 rs864321649 5:172660104-172660104 5:173233101-173233101
16 NKX2-5 NM_004387.4(NKX2-5):c.391G>A (p.Glu131Lys)SNV Pathogenic 219168 rs864321648 5:172660156-172660156 5:173233153-173233153
17 NKX2-5 NM_004387.4(NKX2-5):c.335-1G>TSNV Pathogenic 219165 rs864321645 5:172660213-172660213 5:173233210-173233210
18 ABL1 NM_005157.6(ABL1):c.1009G>A (p.Ala337Thr)SNV Pathogenic 374794 rs1060499548 9:133748348-133748348 9:130872961-130872961
19 ABL1 NM_005157.6(ABL1):c.677A>G (p.Tyr226Cys)SNV Pathogenic 374795 rs1060499547 9:133738277-133738277 9:130862890-130862890
20 TBX5 NM_080717.3(TBX5):c.835_837delinsAC (p.Glu279fs)indel Likely pathogenic 495731 rs1555223294 12:114793907-114793909 12:114356102-114356104
21 TBX5 NM_080717.3(TBX5):c.835_837delinsAG (p.Glu279fs)indel Likely pathogenic 495732 rs1555223294 12:114793907-114793909 12:114356102-114356104
22 NOTCH1 NM_017617.5(NOTCH1):c.1810del (p.Ile604fs)deletion Likely pathogenic 692037 9:139410028-139410028 9:136515576-136515576
23 NKX2-5 NM_004387.4(NKX2-5):c.73C>T (p.Arg25Cys)SNV Conflicting interpretations of pathogenicity 9008 rs28936670 5:172662014-172662014 5:173235011-173235011
24 NKX2-5 NM_004387.4(NKX2-5):c.61G>C (p.Glu21Gln)SNV Conflicting interpretations of pathogenicity 9009 rs104893904 5:172662026-172662026 5:173235023-173235023
25 TTR NM_000371.4(TTR):c.328C>A (p.His110Asn)SNV Conflicting interpretations of pathogenicity 13427 rs121918074 18:29175210-29175210 18:31595247-31595247
26 PSEN1 NM_000021.4(PSEN1):c.998A>G (p.Asp333Gly)SNV Conflicting interpretations of pathogenicity 18156 rs121917809 14:73678519-73678519 14:73211811-73211811
27 MYPN NM_032578.4(MYPN):c.3481C>A (p.Leu1161Ile)SNV Conflicting interpretations of pathogenicity 31819 rs138313730 10:69959320-69959320 10:68199563-68199563
28 PRKAG2 NM_016203.4(PRKAG2):c.247C>T (p.Pro83Ser)SNV Conflicting interpretations of pathogenicity 45711 rs148791216 7:151478457-151478457 7:151781371-151781371
29 TTN NM_001267550.2(TTN):c.16303G>A (p.Val5435Met)SNV Conflicting interpretations of pathogenicity 46614 rs72648937 2:179597600-179597600 2:178732873-178732873
30 TTN NM_001267550.2(TTN):c.5479G>T (p.Ala1827Ser)SNV Conflicting interpretations of pathogenicity 47184 rs141213991 2:179641112-179641112 2:178776385-178776385
31 NOTCH1 NM_017617.5(NOTCH1):c.4168C>A (p.Pro1390Thr)SNV Conflicting interpretations of pathogenicity 134935 rs191645600 9:139400180-139400180 9:136505728-136505728
32 GATA4 NM_002052.5(GATA4):c.909+25G>ASNV Conflicting interpretations of pathogenicity 139595 rs147860174 8:11607770-11607770 8:11750261-11750261
33 GATA4 NM_002052.5(GATA4):c.997+56C>ASNV Conflicting interpretations of pathogenicity 139596 rs804280 8:11612698-11612698 8:11755189-11755189
34 DMD NM_004006.2(DMD):c.8083C>T (p.Pro2695Ser)SNV Conflicting interpretations of pathogenicity 497501 rs755445214 X:31645924-31645924 X:31627807-31627807
35 AKAP9 NM_005751.4(AKAP9):c.7208A>G (p.Glu2403Gly)SNV Conflicting interpretations of pathogenicity 519379 rs150102469 7:91708655-91708655 7:92079341-92079341
36 CERS1 , GDF1 NM_001492.6(GDF1):c.1091T>C (p.Met364Thr)SNV Conflicting interpretations of pathogenicity 522571 rs374016704 19:18979434-18979434 19:18868625-18868625
37 MYOT NM_006790.2(MYOT):c.398C>T (p.Pro133Leu)SNV Conflicting interpretations of pathogenicity 533010 rs779568205 5:137211559-137211559 5:137875870-137875870
38 GATA4 NM_002052.5(GATA4):c.*1256A>TSNV Conflicting interpretations of pathogenicity 433026 rs12458 8:11617240-11617240 8:11759731-11759731
39 RBM20 NM_001134363.3(RBM20):c.3169C>T (p.Arg1057Trp)SNV Conflicting interpretations of pathogenicity 470608 rs199830512 10:112581546-112581546 10:110821788-110821788
40 GATA4 NM_002052.5(GATA4):c.1146+129C>TSNV Conflicting interpretations of pathogenicity 433022 rs116052854 8:11614721-11614721 8:11757212-11757212
41 GATA4 NM_002052.5(GATA4):c.1146+177C>TSNV Conflicting interpretations of pathogenicity 433023 rs12156163 8:11614769-11614769 8:11757260-11757260
42 GATA4 NM_002052.5(GATA4):c.1147-107A>GSNV Conflicting interpretations of pathogenicity 433015 rs745379 8:11615695-11615695 8:11758186-11758186
43 GATA4 NM_002052.5(GATA4):c.*852G>ASNV Conflicting interpretations of pathogenicity 433024 rs804290 8:11616836-11616836 8:11759327-11759327
44 GATA4 NM_002052.5(GATA4):c.997+200G>ASNV Conflicting interpretations of pathogenicity 433020 rs3729851 8:11612842-11612842 8:11755333-11755333
45 GATA4 NM_002052.5(GATA4):c.617-116T>CSNV Conflicting interpretations of pathogenicity 433016 rs3735819 8:11606312-11606312 8:11748803-11748803
46 GATA4 NM_002052.5(GATA4):c.617-64G>CSNV Conflicting interpretations of pathogenicity 433017 rs10503425 8:11606364-11606364 8:11748855-11748855
47 TTN NM_001267550.2(TTN):c.102271C>T (p.Arg34091Trp)SNV Conflicting interpretations of pathogenicity 178157 rs140319117 2:179399071-179399071 2:178534344-178534344
48 MYOT NM_006790.2(MYOT):c.323A>C (p.Asn108Thr)SNV Conflicting interpretations of pathogenicity 281070 rs142416150 5:137206663-137206663 5:137870974-137870974
49 MYH6 NM_002471.3(MYH6):c.2575G>T (p.Gly859Trp)SNV Uncertain significance 191718 rs369274077 14:23863387-23863387 14:23394178-23394178
50 NKX2-5 NM_004387.4(NKX2-5):c.335-12G>ASNV Uncertain significance 219166 rs864321646 5:172660224-172660224 5:173233221-173233221

Copy number variations for Heart Disease from CNVD:

7 (show top 50) (show all 63)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17306 1 142400000 148000000 Duplication Heart disease
2 17316 1 142400000 148000000 Microdeletion Congenital heart defect
3 17332 1 142400000 148000000 Rearrangements Congenital heart defect
4 18950 1 148000000 149600000 Copy number Congenital heart defect
5 38769 10 104900000 105700000 Duplication CALHM1 Heart disease
6 38770 10 104900000 105700000 Duplication CALHM2 Heart disease
7 38771 10 104900000 105700000 Duplication PDCD11 Heart disease
8 40012 10 123100000 135374737 Deletion Heart disease
9 44160 10 52900000 70600000 Copy number TFAM Heart failure
10 44161 10 52900000 70600000 Copy number TFAM Heart failure
11 50206 11 115400000 134452384 Duplication Heart disease
12 65746 12 21200000 26300000 Deletion SLCO1A2 Heart disease
13 70609 12 63400000 66000000 Duplication Heart disease
14 81035 14 100400000 106368585 Deletion Congenital heart defect
15 83025 14 19100000 23600000 Duplication Heart disease
16 84174 14 23851199 23877482 Amplificationlication MYH6 Congenital heart defects
17 86222 14 55800000 61200000 Duplication Heart disease
18 87066 14 69300000 72900000 Duplication Heart disease
19 92217 8 104452961 104464393 Duplication CTHRC1 Congenital heart defect
20 97907 16 14700000 16700000 Duplication or deletion Congenital heart defects
21 106854 17 1 3600000 Duplication Heart disease
22 108227 17 19227347 19231086 Duplication MFAP4 Congenital heart defect
23 115120 17 54900000 58400000 Microdeletion TBX2 Heart disease
24 115122 17 54900000 58400000 Microdeletion TBX4 Heart disease
25 119183 18 1 2900000 Duplication Heart disease
26 119195 18 1 7200000 Duplication Heart disease
27 120625 18 2900000 17300000 Duplication Heart disease
28 131218 19 53800000 59100000 Duplication Heart disease
29 155473 20 55900000 57900000 Duplication Heart disease
30 159146 21 40466951 40489050 Loss DSCAM Congenital heart defects
31 159325 21 41568947 41572987 Loss BACE2 Congenital heart defects
32 159387 21 42123984 42136309 Loss PRDM15 Congenital heart defects
33 159403 21 42223189 42226495 Loss C2CD2 Congenital heart defects
34 159959 21 46367207 46399800 Gain COL6A2 Congenital heart defects
35 160218 22 11800000 24300000 Deletion Congenital heart defect
36 160262 22 11800000 24300000 Microdeletion Congenital heart defect
37 160288 22 11800000 49691432 Duplication CHDs Congenital heart defect
38 160785 22 16300000 24300000 Deletion Congenital heart defect
39 160789 22 16300000 24300000 Deletion Heart disease
40 160812 22 16300000 24300000 Deletion TBX1 Congenital heart defect
41 160832 22 16300000 24300000 Microdeletion Congenital heart defect
42 160833 22 16300000 24300000 Microdeletion Congenital heart defect
43 213399 6 45200000 51100000 Duplication RUNX2 Heart disease
44 213400 6 45200000 51100000 Duplication SUPT3H Heart disease
45 213401 6 45200000 51100000 Duplication TNFRSF21 Heart disease
46 221295 7 142800000 147500000 Duplication TPK1 Heart disease
47 221880 7 147500000 152200000 Deletion GALNT11 Heart disease
48 222426 7 15200000 19500000 Deletion TMEM195 Heart disease
49 222427 7 15200000 19500000 Duplication PRPS1L1 Heart disease
50 223375 7 19500000 24900000 Duplication RAPGEF5 Heart disease

Expression for Heart Disease

Search GEO for disease gene expression data for Heart Disease.

Pathways for Heart Disease

Pathways related to Heart Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 MIR23A MIR214 MIR210 MIR21 MIR195 ABL1
2 11.06 NKX2-5 MYH6 GATA4
3 10.83 MIR23A MIR210 ABL1
4 10.66 NKX2-5 GATA4
5 10.03 NKX2-5 GATA4

GO Terms for Heart Disease

Biological processes related to Heart Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 MIR23A MIR21 GATA4 ABL1
2 cardiac muscle tissue development GO:0048738 9.57 NKX2-5 GATA4
3 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR214 MIR21
4 regulation of protein kinase B signaling GO:0051896 9.55 MIR21 GATA4
5 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.54 MIR320A MIR195
6 cardiovascular system development GO:0072358 9.52 NKX2-5 ABL1
7 positive regulation of connective tissue replacement GO:1905205 9.51 MIR214 MIR195
8 adult heart development GO:0007512 9.49 NKX2-5 MYH6
9 atrial septum morphogenesis GO:0060413 9.48 NKX2-5 GATA4
10 negative regulation of oxidative stress-induced cell death GO:1903202 9.46 MIR195 GATA4
11 cardiac ventricle morphogenesis GO:0003208 9.43 NKX2-5 GATA4
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.37 MIR210 MIR21
13 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.33 NKX2-5 MIR21